Development of the DVH management software for the biologically-guided evaluation of radiotherapy plan.
10.3857/roj.2012.30.1.43
- Author:
Bokyong KIM
;
Hee Chul PARK
;
Dongryul OH
;
Eun Hyuk SHIN
;
Yong Chan AHN
;
Jinsung KIM
;
Youngyih HAN
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Dose volume histogram;
Normal tissue complication probability
- MeSH:
Humans;
Incidence;
Lung Neoplasms;
Medical Records;
Radiation Pneumonitis;
Retrospective Studies
- From:Radiation Oncology Journal
2012;30(1):43-48
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To develop the dose volume histogram (DVH) management software which guides the evaluation of radiotherapy (RT) plan of a new case according to the biological consequences of the DVHs from the previously treated patients. MATERIALS AND METHODS: We determined the radiation pneumonitis (RP) as an biological response parameter in order to develop DVH management software. We retrospectively reviewed the medical records of lung cancer patients treated with curative 3-dimensional conformal radiation therapy (3D-CRT). The biological event was defined as RP of the Radiation Therapy Oncology Group (RTOG) grade III or more. RESULTS: The DVH management software consisted of three parts (pre-existing DVH database, graphical tool, and Pinnacle3 script). The pre-existing DVH data were retrieved from 128 patients. RP events were tagged to the specific DVH data through retrospective review of patients' medical records. The graphical tool was developed to present the complication histogram derived from the pre-existing database (DVH and RP) and was implemented into the radiation treatment planning (RTP) system, Pinnacle3 v8.0 (Phillips Healthcare). The software was designed for the pre-existing database to be updated easily by tagging the specific DVH data with the new incidence of RP events at the time of patients' follow-up. CONCLUSION: We developed the DVH management software as an effective tool to incorporate the phenomenological consequences derived from the pre-existing database in the evaluation of a new RT plan. It can be used not only for lung cancer patients but also for the other disease site with different toxicity parameters.
